A series of six new ferrocene-carbohydrate conjugates was prepared from pentose and hexose sugar derivatives. These include the ferrocenecarbaldehyde acetal 2, four ferrocenyltriazoles 4a-d derived from furanose sugar and the ferrocenyltriazole 4e derived from a pyranose sugar. The compounds were characterised by spectroscopic means and the structures of the new conjugates 2 and 4a were determined by means of X-ray crystallography. A UV/Vis study of these compounds performed in aqueous solutions under physiological conditions confirmed their stability. The CD spectral analysis shows the effect of the nature of substituents of the carbohydrate moieties. The electrochemical studies conducted in a buffer solution display one-electron reversible oxidation processes for these compounds. These results indicate that the compounds are suitable for conducting bio-[a]
Amide-triazole linker incorporated ferrocene-carbohydrate conjugates were prepared by adopting a regiospecific copper(II)-catalysed 1,3-cycloaddition of ferrocenoyl propargylamide and isopropylidene/acetyl protected carbohydrate azides. Hydrophilic ferrocene glycoside with an amide-triazole linker was synthesised by deacetylation of the hydroxyl groups. All the new compounds were characterised by UV-visible and electrochemical studies and they were found to be stable in organic solvents as well as in the buffer system under physiological conditions (pH = 7.0). The diffusion coefficient (D(f)) of the conjugates was also calculated by means of cyclic voltammetric studies. It was observed that while the molecular weight of the compounds had no significant effect on the diffusion coefficient, the hydrophobic/hydrophilic nature of the carbohydrate scaffold displayed varied diffusion coefficient values. Stabilization of the compounds in buffer solution under physiological pH led to almost identical diffusion coefficient values. The compounds derived from xylose and ribose exhibited cytotoxicity on hormone-dependent and hormone-independent breast cancer cell lines, whereas the conjugates derived from glucose and galactose were found to be non-toxic in nature. The compounds did not show any antimicrobial activity against Gram-positive and Gram-negative pathogens.
We report here an efficient protocol for the one-pot facile synthesis of spiro[indeno[1,2-b]quinoxaline-11,3′-pyrrolizine]heterocyclic scaffolds and their AChE inhibitory studies.
The reactions of the nitrile-stabilized complex [Re3(μ-H)3(CO)11(MeCN)] (1) and of the
unsaturated complex [Re4(μ-H)4(CO)12] (2) with 2-amino-6-methylpyridine (Hampy), 2-mercaptopyridine (Hmerpy), and 2-hydroxy-6-methylpyridine (Hhympy) have been studied.
Complex 1 reacts slowly with Hampy and Hmerpy (refluxing toluene, 5−7 h) to give the
binuclear derivatives [Re2(μ-ampy)2(CO)6] (3) and [Re2(μ-merpy)2(CO)6] (4), but no reaction
is observed between 1 and Hhympy under analogous conditions. Complex 2 reacts with
Hampy and Hmerpy (refluxing 1,2-dichloroethane, 10−20 min) to give the trinuclear anionic
derivatives [Re3(μ-H)3(μ3-ampy)(CO)9]- (5) and [Re3(μ-H)3(μ3-merpy)(CO)9]- (6), which have
been isolated as pyridinium ([H2ampy]5) or triethylammonium ([HNEt3]5, [HNEt3]6) salts.
Under analogous conditions, the reaction of 2 with Hhympy gives an inseparable mixture of
compounds. The X-ray structures of [HNEt3]5 and [HNEt3]6 confirm that the three edges
of the clusters are spanned by hydride ligands, that the ampy (in 5) and merpy (in 6) are
attached to the three Re atoms, and that there are hydrogen-bonding interactions in the
solid state between some carbonyl oxygen atoms and the NH fragments of the ampy ligand
(in 5) and the triethylammonium cation (in 5 and 6).
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.